Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian Clinical Trial Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentPresbyterian Health PlanPolicy 3.6

    Clinical Trials, Routine Patient Care Costs for Commercial

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy 3.6 alerts

    Get alerted when Policy 3.6 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of routine medical care costs for commercial members participating in approved interventional clinical trials for cancer or other life-threatening diseases or conditions. Coverage is subject to the member's benefit plan, applicable utilization management requirements, prior authorization, and the trial qualification and routine-cost criteria described in the policy.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyClinical Trials, Routine Patient Care Costs for Commercial
    Policy CodePolicy N/A
    Change TypeClarificationno material coverage change
    Effective DateN/A
    Next Review DateNov 19, 2025
    Key ActionObtain prior authorization for routine medical care costs when a member participates in an approved clinical trial for cancer or another life-threatening disease or condition.
    SourceLink
    POLICY UPDATE CHANGES

    The 2025 annual review clarified prior authorization requirements without making a material clinical or coverage change.

    Phase I-IVEligible clinical trial phases
    RequiredPrior authorization for routine trial care
    3HCPCS clinical-trial phase codes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Clinical-trial modifiers
    ExcludedInvestigational items and study-only services

    Approved Clinical Trial Coverage

    Approved Clinical Trial Definition

    An approved clinical trial is a Phase I, II, III, or IV clinical trial that meets the applicable disease and sponsorship, FDA, or drug-trial exemption requirements below.

    ALL of the following

    • The clinical trial is Phase I, II, III, or IV.
    • The clinical trial is conducted in relation to the prevention, detection, or treatment of approved cancer or another life-threatening illness or condition. A life-threatening illness or condition is one from which there is a probable likelihood of death unless the course of the illness or condition is interrupted.
    • ONE of the following

      • A. Federally funded trial

        • The study or investigation is approved or funded, including through in-kind contributions, by one or more of the following: the National Institutes of Health (NIH), including the National Cancer Institute (NCI); the Centers for Disease Control and Prevention (CDC); the Agency for Healthcare Research and Quality (AHRQ); the Centers for Medicare and Medicaid Services (CMS); a cooperative group or center of any of these entities, the Department of Defense (DOD), or the Veterans Administration (VA); or a qualified nongovernmental research entity identified in NIH guidelines for center support grants.
        • OR

          • The study or investigation is conducted by the Department of Veterans Affairs, the Department of Defense, or the Department of Energy and has been reviewed and approved through a peer-review system determined by the Secretary of Health and Human Services to meet the required standards.
          • Required peer-review standards

            • The peer-review system is comparable to the NIH system of peer review.
            • The peer-review system assures unbiased review to the highest scientific standards by qualified individuals who have no interest in the outcome of the review.
      • B. The study or investigation is conducted under an investigational new drug application reviewed by the U.S. Food and Drug Administration (FDA).
      • C. The study or investigation is a drug trial that is exempt from having an investigational new drug application.

    Member and Trial Eligibility

    Coverage is available when ALL applicable member, trial, disease, benefit-plan, and authorization requirements are met.

    ALL of the following

    • The member is eligible to participate in an approved clinical trial according to the trial protocol for treatment of cancer or another life-threatening disease or condition.
    • The participant or beneficiary provides medical and scientific information establishing that participation in the trial is appropriate based on the member meeting the applicable conditions.
    • The clinical trial has a written protocol describing a scientifically sound study.
    • The clinical trial has been approved by all relevant institutional review boards (IRBs) before participants are enrolled.
    • The member meets all relevant plan requirements, including precertification, registration, and referrals.

    Routine Patient Care Costs

    Routine patient care costs are covered when ALL of the following requirements are met.

    ALL of the following

    • The item or service is consistent with coverage provided under the member's plan and is typically covered for a qualified individual who is not enrolled in a clinical trial.
    • The item or service is required solely for ONE or more of the following

      • The provision of the experimental or investigational service or item, such as infusion administration services to deliver an investigational drug.
      • Clinically appropriate monitoring of the effects of the experimental or investigational service or item, such as laboratory tests and imaging performed at a frequency consistent with signs and symptoms and other standards of care for the diagnosis or treatment type.
      • The prevention of complications.

    Routine patient care costs do not include the investigational item, device, or service itself. They also do not include items or services provided solely to satisfy data-collection or analysis needs when those items or services are not used in the member's direct clinical management.

    Items and services provided by research sponsors free of charge to any person enrolled in the trial are not covered as routine patient care costs.

    Travel, lodging, and meals are covered only when those benefits are included under the member's benefit plan.

    Services performed at a frequency dictated by the study protocol, rather than by clinical signs and symptoms or other standards of care for the applicable diagnosis or treatment type, are not routine patient care costs. For example, laboratory tests and imaging studies performed solely at protocol-directed frequency are excluded when that frequency is not clinically appropriate.

    A service that is clearly inconsistent with widely accepted and established standards of care for the particular diagnosis is not covered as a routine patient care cost.

    Clinical trials that do not meet the approved clinical-trial requirements, routine items or services obtained out of network when the plan has no non-network benefits, and other items or services that do not meet specified criteria under applicable medical or drug policies are not covered as routine patient care costs.

    Billing and Coding References

    HCPCS CodesHCPCS
    S9988Services provided as a part of a phase I clinical trial.
    S9990Services provided as a part of a phase II clinical trial.
    S9991Services provided as a part of a phase III clinical trial.
    ICD-10 Diagnosis CodeICD-10
    Z00.6Encounter for examination for normal comparison and control in clinical research program. (Includes: Examination of participant or control in clinical research program)
    Modifier(s)Modifier
    Q0Investigational clinical service provided in a clinical research study that is in an approved clinical research study.
    Q1Routine clinical service provided in a clinical research study that is in an approved clinical research study.
    Other referenced CPT codeCPT
    99199CPT code referenced in the publication history; the policy does not provide a code description. The code has no prior authorization requirement.

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for routine medical care costs for cancer or other life-threatening disease or conditions when the member participates in an approved clinical trial. Submit the request through Pres Online; the requirement applies to both in-network and out-of-network routine care when the member's benefit plan permits out-of-network coverage.

    • Submit requests through Pres Online: https://ds.phs.org/preslogin/index.jsp
    • Routine care remains subject to applicable utilization management, precertification, registration, referral, and other plan requirements.
    Documentation Required

    Submit Clinical Trial Qualification Information

    Providers or members must provide medical and scientific information establishing that the individual's participation in the clinical trial is appropriate and consistent with the trial protocol for treatment of cancer or another life-threatening disease or condition.

    Policy Background

    A clinical trial is a research study or protocol designed to evaluate the safety or effectiveness of experimental drugs, devices, or treatments in humans. Routine patient care costs are items and services that would generally be available and furnished even if the member were not enrolled in the trial, including medically necessary care to administer or monitor the investigational service, prevent complications, or treat reasonable and necessary complications arising from it.

    Key Terms

    Clinical Trial
    Clinical trialA research study or protocol involving experimental drugs, devices, or treatments in humans.
    Primary purposeTo test safety and/or effectiveness.
    対象Experimental drugs, devices, or treatments administered or evaluated in humans.
    Routine Care Items and Services
    Routine care items and servicesItems and services otherwise generally available to beneficiaries.
    Provided duringFurnished during a clinical study.
    Would otherwise be furnished
    Policy Summary
    PayerPresbyterian Health Plan
    PolicyClinical Trials, Routine Patient Care Costs for Commercial
    Policy CodePolicy N/A
    Change TypeClarificationno material coverage change
    Effective DateN/A
    Next Review DateNov 19, 2025
    Key ActionObtain prior authorization for routine medical care costs when a member participates in an approved clinical trial for cancer or another life-threatening disease or condition.
    SourceLink
    On This Page
    Approved Clinical Trial CoverageBilling and Coding ReferencesAuthorization, Documentation, and Denial RisksPolicy BackgroundKey Terms
  1. Prior authorization is obtained for routine medical care costs for cancer or a life-threatening disease or condition when the member participates in an approved clinical trial. Requests may be submitted through Pres Online: https://ds.phs.org/preslogin/index.jsp.
  2. All utilization-management rules and coverage policies that apply to routine care for members who are not participating in a trial also apply to routine care for members participating in clinical trials.
  3. Out-of-network services, including out-of-state services, are covered only when the member's health benefit plan allows out-of-network coverage.
  4. Routine clinical-trial documentation submission is not required initially; however, Presbyterian Health Plan may request documentation at any time to verify that the trial meets current scientific-merit standards and has the relevant IRB approval(s).
  5. Reasonable and necessary care arising from the provision of an experimental or investigational service or item.
  6. The service is medically necessary under the applicable plan, medical policy, and drug policy requirements.
  7. Medically necessary treatment for conditions that arise as unexpected complications from participation in the clinical trial is covered, subject to applicable plan requirements.
    • Use clinical information demonstrating the member meets the trial's participation conditions.
    • Support that the trial is an approved clinical trial under the policy definition.
    Documentation Required

    Maintain Supporting Records

    When PHP relies on external guidelines or source materials to determine coverage, providers are expected to maintain or have access to appropriate supporting documentation and provide it when requested.

    • Review the References section for the applicable source materials, including guidelines such as LCDs, NCDs, MCG, or NCCN.
    • Documentation may be requested to support coverage.
    Denial Risk

    Denial Risk: Trial Is Not an Approved Clinical Trial

    Denial risk: routine patient care costs may be denied when the clinical trial does not meet the policy's approved-trial definition. The trial must be a Phase I, II, III, or IV trial addressing an approved cancer or other life-threatening illness or condition and must satisfy an approved funding, FDA investigational new drug, or qualifying drug-trial exemption pathway.

    • Federally funded trials must meet the listed governmental, cooperative-group, qualified research-entity, or qualifying peer-review requirements; NIH/NCI-funded trials must also provide an NCT number.
    • Alternatively, the study must be conducted under an FDA-reviewed investigational new drug application or be a drug trial exempt from that requirement.
    Denial Risk

    Denial Risk: Insufficient Medical or Scientific Support

    Denial risk: coverage may be denied when the submitted medical or scientific information does not establish that the member's participation in the trial is appropriate under the applicable conditions and protocol.

    • Provide information supporting the member's eligibility and appropriateness for participation.
    • The trial must concern treatment, prevention, or detection of cancer or another life-threatening disease or condition.
    Denial Risk

    Denial Risk: Protocol or IRB Requirements Not Met

    Denial risk: the clinical trial must have a written protocol describing a scientifically sound study and must be approved by all relevant institutional review boards before participants are enrolled.

    • Missing or inadequate scientifically sound protocol documentation may prevent coverage.
    • Required IRB approval must be in place before enrollment.
    • Failure to satisfy other applicable trial qualification, utilization management, precertification, registration, referral, or plan requirements may affect coverage.
    Denial Risk

    Denial Risk: Excluded Routine-Cost Category

    Denial risk: routine patient care costs exclude investigational items or services themselves and services that do not meet the policy's routine-cost criteria or applicable medical and drug policies.

    • Exclude items and services provided solely for study data collection or analysis, including testing performed at protocol-driven frequencies inconsistent with signs, symptoms, or accepted standards of care.
    • Exclude services clearly inconsistent with widely accepted standards of care and items or services provided free by the research sponsor.
    • Exclude routine costs when non-network benefits do not exist, and costs for clinical trials that fail the policy requirements.
    • Travel, lodging, and meals are covered only when included in the member's benefit.
    Would be furnished even if the beneficiary were not enrolled in a clinical study.
    Life-Threatening Disease or Condition
    Life-threatening disease or conditionA disease or condition for which there is a probable likelihood of death.
    Required circumstanceThe risk of death is probable unless the course of the disease or condition is interrupted.
    ApplicationIncludes a life-threatening illness or condition addressed by an approved clinical trial.
    Approved Clinical Trial
    Approved clinical trialA Phase I, II, III, or IV clinical trial.
    Clinical purposeConducted for the prevention, detection, or treatment of approved cancer or another life-threatening illness or condition.
    Qualifying pathwayThe trial must be federally funded, conducted under an investigational new drug application reviewed by the U.S. FDA, or be a drug trial exempt from such an application.